Clinical trials · San Francisco, CA
Alzheimer’s disease clinical trials in San Francisco
We’re tracking 29 recruiting alzheimer’s disease studies with a site in or near San Francisco — including Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near San Francisco
- NCT06416072Enrolling by invitation
Blood marker study for people not eligible for Alzheimer's prevention trials
This study looks at blood markers in people who were part of an early Alzheimer's prevention study but did not qualify for it because their amyloid levels were too low. It aims to understand brain changes and possibly find ways to detect Alzheimer's even earlier.
San Francisco, CaliforniaAges 55–80 - NCT05641688RecruitingPhase 3
PET brain scan study for people with terminal illness
This Phase 3 study tests an amyloid/tau PET brain imaging agent (called [18F]PI-2620). It aims to see how well the scan helps with brain pathology findings in people who are expected to have a life expectancy of 1 year or less.
San Francisco, CaliforniaAges 50 years+ - NCT06860828Enrolling by invitation
Football players and brain health study: DIAGNOSE CTE
This study looks at brain changes in former college and professional football players, people with memory problems, and healthy controls. It aims to learn more about chronic traumatic encephalopathy (CTE) and Alzheimer's disease.
San Francisco, CaliforniaAges 50 years+ - NCT05617014Enrolling by invitation
ADNI4 study for early Alzheimer’s with brain imaging tests
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
San Francisco, CaliforniaAges 55–90 - NCT06957418RecruitingPhase 2
Alzheimer's tau drug study for early stage patients
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
San Francisco, CaliforniaAges 50–80 - NCT07167966Enrolling by invitationPhase 2
Alzheimer's tau vaccine study (AADvac1)
This trial tests a vaccine that targets tau tangles in the brain, which are linked to Alzheimer's. It is part of a larger platform study that combines different experimental treatments.
San Francisco, CaliforniaAges 50–80 - NCT07169578RecruitingPhase 3
A study of trontinemab for early Alzheimer's disease
This trial tests a new drug called trontinemab for people with early Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
San Francisco, CaliforniaAges 50–90 - NCT05374278RecruitingPhase 1/Phase 2
PET scan test for a dementia brain tracer
This early-phase study tests a new PET scan tracer that targets a brain chemical transport system involved in dementia. It aims to see if the tracer can safely and clearly show brain changes, which could help future dementia diagnosis or tracking.
San Francisco, CaliforniaAges 40–75 - NCT07033494RecruitingPhase 2
Study of MK-2214 for early Alzheimer's disease
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
San Francisco, CaliforniaAges 50–85 - NCT05395624RecruitingPhase 1/Phase 2
Safety imaging study of a PET tracer in ALS, Alzheimer, MS, Parkinson
This early-phase study tests the safety of a radioactive tracer (“18F-OP-801”) and how the tracer moves through the body (biodistribution) in people with ALS, Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and in healthy volunteers. It also measures how the body processes the tracer (“pharmacokinetics”) to support future studies.
San Francisco, CaliforniaAges 18–80 - NCT07260253Recruiting
Remote brain stimulation for language in primary progressive aphasia
This study tests if a non-invasive brain stimulation technique called tDCS, done at home with remote supervision, can help improve language skills in people with the logopenic variant of primary progressive aphasia (PPA).
San Francisco, CaliforniaAges 40 years+ - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Oakland, CaliforniaAges 50–90 - NCT06847321RecruitingPhase 2
Testing LHP588 for Alzheimer's linked to a mouth bacteria
This trial tests a new medication, LHP588, for people with Alzheimer's who also have a common mouth bacteria called P. gingivalis. The goal is to see if targeting this bacteria can help slow down memory loss.
Oakland, CaliforniaAges 55–80 - NCT07170150RecruitingPhase 3
A study of trontinemab for early Alzheimer's disease
This trial tests an investigational drug called trontinemab in people with early symptomatic Alzheimer's disease. It aims to see if it can slow down memory and thinking problems.
Oakland, CaliforniaAges 50–90 - NCT04800588Recruiting
Computer tests to study early Alzheimer’s changes
This study uses computer and touch-screen tasks to measure thinking changes in people who may be in the early, symptom-free stage of Alzheimer’s disease. It aims to understand how these brain-related changes show up on testing, which could help future detection or tracking.
Berkeley, CaliforniaAges 18–89 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Walnut Creek, CaliforniaAges 55–90 - NCT04804241RecruitingPhase 2
Senicapoc for early Alzheimer’s symptoms
This Phase 2 study tests whether the drug senicapoc can slow or improve symptoms in people with early Alzheimer’s disease or mild memory impairment. You would have a 50/50 chance of getting senicapoc or a placebo (inactive pill), along with regular study visits and testing.
Walnut Creek, CaliforniaAges 55–85 - NCT06126224RecruitingPhase 3
Testing KarXT for Alzheimer's-related psychosis
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
Walnut Creek, CaliforniaAges 55–90 - NCT05980949RecruitingPhase 3
Long-term safety study of KarXT for Alzheimer's psychosis
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
Walnut Creek, CaliforniaAges 55–90 - NCT07602582RecruitingPhase 3
Donanemab Extension Study for Alzheimer's Disease
This is a follow-up study for people who already completed a previous donanemab trial (AACM). Donanemab is a medication designed to slow cognitive decline in early Alzheimer's disease by targeting amyloid buildup in the brain.
Walnut Creek, CaliforniaAges 55 years+ - NCT06540833RecruitingPhase 2
Study of ITI-1284 for psychosis in Alzheimer's disease
This trial tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis (hallucinations or delusions) in people with Alzheimer's disease. It may be an option for patients who have both Alzheimer's and related psychotic symptoms.
Walnut Creek, CaliforniaAges 55 years+ - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Walnut Creek, CaliforniaAges 55–90 - NCT05511363RecruitingPhase 3
Study of a new medicine for psychosis in Alzheimer's disease
This trial tests a new drug called KarXT to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. If you or a loved one has Alzheimer's and experiences these symptoms, this study might offer a new treatment option.
Walnut Creek, CaliforniaAges 55–90 - NCT07178210Recruiting
Robotic surgery for lymphatic drainage in Alzheimer's disease
This study tests a new robotic-assisted surgery to improve drainage of lymph fluid in the neck, which may help slow the progression of Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have specific biomarkers.
Palo Alto, CaliforniaAges 50 years+
Hear when a new Alzheimer’s disease trial opens near San Francisco, CA
We’ll email you when one opens near San Francisco, CA — at most once a week, no account needed, unsubscribe anytime.
Alzheimer’s disease trials in other cities
Where these studies are running near San Francisco
Institutions with a site for the recruiting alzheimer’s disease studies listed above.
- University of California, San Francisco · 7 studies
- Sunwise Clinical Research · 4 studies
- Oakland Clinical · 3 studies
- Stanford University · 3 studies
- University of California, Davis · 3 studies
- UCSF Health · 2 studies
- Infectious Disease Doctors Medical Group, APC
- Local Institution - 1007
What taking part in a alzheimer’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting alzheimer’s disease studies in California.
Common questions
- Are there alzheimer’s disease clinical trials near San Francisco?
- Yes. We're currently tracking 29 recruiting alzheimer’s disease studies with a site near San Francisco, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alzheimer’s disease study near San Francisco?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in San Francisco to take part?
- Not necessarily. These studies have a site near San Francisco, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alzheimer’s disease studies open near San Francisco regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.